Summit Therapeutics' Lung Cancer Drug Ivonescimab Clears Key FDA Hurdle, Sets Stage for November Decision
The FDA has accepted Summit Therapeutics' application for its bispecific antibody ivonescimab, targeting a specific form of advanced lung cancer. A final regulatory decision is set for November 14, following positive late-stage trial data.